by Cal Strode | Nov 2, 2026
Back in August 2016, Signals celebrated ten years of induced pluripotent stem cells (iPSCs) by hosting its first-ever blog carnival, in which contributors each wrote posts answering the same question: With useful treatments for diseases like heart failure and diabetes...
by Lyla El-Fayomi | Oct 19, 2026
Last week, optogenetics finally claimed the Nobel Prize in Physiology or Medicine. Most of the mainstream coverage thus far has placed a lot of emphasis on “turning parts of the brain on and off” in explaining the win; however, scientists had been doing that for years...
by Stacey Johnson | Sep 18, 2026
I went down a bit of a rabbit hole the other day, as one often does on the internet and/or social media. In my defence, I was looking for inspiration for my next blog post – this one – and I found some. It started with this parody song about placebos, by anesthetist...
by Stacey Johnson | Jul 23, 2026
“Regulatory approval does not translate to dollars for a company, nor does it lead to patients being treated. Without reimbursement, all of the efforts of translation and development are lost.” My former colleague, Mark Curtis, wrote these words back when he blogged...
by Stacey Johnson | Jul 9, 2026
Celebrity health stories often dominate headlines, but their impact extends beyond entertainment news. High-profile diagnoses can raise awareness of rare diseases, increase participation in clinical trials, influence health policy, and accelerate investment in...
by Michael May | Jun 9, 2026
Fifteen years ago, regenerative medicine in Canada stood at an inflection point. The science was world-class, the academic talent was undeniable, and the promise of cell and gene therapies was beginning to capture global attention. Yet there was a critical problem:...
Comments